Healthcare professionals

On this page, you will find information on the Agency’s activities that are most relevant to healthcare professionals, including news, and events. You can contribute to the Agency’s work by responding to public consultations. Learn more about how Healthcare Professionals are actively involved in the work of the Agency.

• List item

  Human medicines: highlights of 2022

  In 2022, EMA recommended 89 medicines for marketing authorisation. Of these, 41 had a new active substance which had never been authorised in the European Union before. These included two vaccines and two treatments for COVID-19.

• List item

  Questions and answers on interchangeability of biosimilars

  A 'questions and answers' document is available for healthcare professionals, patients and other stakeholders to further address issues related to the interchangeability of biosimilars in EU countries. This complements the information that EMA and the Heads of Medicines Agencies provided in a joint statement on this topic, in September 2022.

• List item

  Guidance on medicine shortages

  Guidance is available on the actions that patients and healthcare professionals can take to help prevent and manage shortages of human medicines in the EU. An infosheet and infocards are also available to summarise the recommendations in the guidance.

• List item

  Celebrating ten years of interactions

  December 2021 marked ten years of cooperation between EMA and healthcare professionals under a formal framework for interaction. Read our short anniversary report to learn about the range of organisations involved, key milestones and future direction. EMA is committed to working closely with its expanding network of healthcare professional organisations and encourages all eligible, not-for-profit organisations to get involved.

• List item

  Revision of 'ICH E6 Good clinical practice guideline'

  The video recording of the ICH web conference on 18 and 19 May on the revision of the ‘ICH E6 Good clinical practice guideline’ to adapt it to advances in clinical trial design and conduct is available. The conference covered ongoing drafting work and ICH’s efforts to involve stakeholders in the process.

• List item

  European medicines agencies network strategy to 2025

  The strategy sets out how the network will continue to enable the supply of safe and effective medicines, in the face of developments in science, medicine, digital technologies, globalisation and emerging health threats, such as the COVID-19 pandemic.

• List item

  Paediatric medicines: progress on action plan

  A progress update is available on the EMA / European Commission action plan for supporting the development of medicines for children. It specifies the status of each action and outlines concrete achievements to December 2020.

• List item